Security
Entrada Therapeutics, Inc. Common Stock · TRDA
TRDANASDAQCommon stockCurrentCIK 1689375Updated Nov 9, 2026
Name history
CycloPorters, Inc. · through Nov 10, 2016
TRDA price & chart
Loading TradingView…
NASDAQ:TRDA on TradingView ↗In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA ↗
Recent filings
10-Q filing
8-K filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
SCHEDULE 13D/A - filed by MPM BioVentures 2014, L.P. regarding Entrada Therapeutics, Inc.
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 412,898,000Source | 554,590,000Source | 298,877,000Source | 448,783,000Source | 581,963,000Source | 335,518,000Source | 486,479,000Source | 510,844,000Source | 377,378,000Source | 526,321,000Source | 469,192,000Source | 252,056,000Source |
| Property, Plant and Equipment, NetUSD | 8,406,000Source | 10,786,000Source | 5,722,000Source | 9,807,000Source | 11,344,000Source | 6,506,000Source | 10,674,000Source | 11,002,000Source | 7,313,000Source | 10,928,000Source | 11,191,000Source | 7,681,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 93,286,000Source | 78,049,000Source | 99,280,000Source | 72,482,000Source | 185,253,000Source | 76,444,000Source | 67,837,000Source | 68,436,000Source | 90,394,000Source | 101,211,000Source | 67,602,000Source | 45,157,000Source |
| Assets, CurrentUSD | 338,257,000Source | 465,335,000Source | 232,704,000Source | 369,146,000Source | 489,536,000Source | 266,872,000Source | 403,193,000Source | 414,172,000Source | 306,252,000Source | 440,039,000Source | 369,771,000Source | 209,875,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 10,223,000Source | 13,388,000Source | 8,883,000Source | 13,954,000Source | 12,116,000Source | 11,226,000Source | 18,634,000Source | 9,244,000Source | 8,719,000Source | 16,361,000Source | 11,924,000Source | 21,163,000Source |
| Operating Lease, Right-of-Use AssetUSD | 62,122,000Source | 73,773,000Source | 57,041,000Source | 65,681,000Source | 76,386,000Source | 58,758,000Source | 68,423,000Source | 78,958,000Source | 60,451,000Source | 71,120,000Source | 81,490,000Source | 25,340,000Source |
| Other Assets, NoncurrentUSD | 163,000Source | 746,000Source | 118,000Source | 199,000Source | 747,000Source | 90,000Source | 239,000Source | 2,762,000Source | 70,000Source | 284,000Source | 2,790,000Source | 5,210,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 72,182,000Source | 132,143,000Source | 65,466,000Source | 69,278,000Source | 152,038,000Source | 64,664,000Source | 69,219,000Source | 241,477,000Source | 71,245,000Source | 97,643,000Source | 226,832,000Source | 39,502,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 4,000Source | 3,000Source | 4,000Source | 4,000Source | 3,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 574,021,000Source | 551,946,000Source | 588,915,000Source | 568,897,000Source | 546,693,000Source | 583,415,000Source | 563,512,000Source | 441,084,000Source | 578,571,000Source | 558,061,000Source | 437,132,000Source | 402,893,000Source |
| Retained Earnings (Accumulated Deficit)USD | -233,930,000Source | -130,475,000Source | -355,574,000Source | -189,796,000Source | -116,443,000Source | -312,811,000Source | -146,693,000Source | -171,474,000Source | -273,094,000Source | -129,344,000Source | -194,970,000Source | -188,285,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 621,000Source | 972,000Source | 66,000Source | 400,000Source | -329,000Source | 246,000Source | 437,000Source | -246,000Source | 652,000Source | -43,000Source | 195,000Source | -2,057,000Source |
| Stockholders' Equity Attributable to ParentUSD | 340,716,000Source | 422,447,000Source | 233,411,000Source | 379,505,000Source | 429,925,000Source | 270,854,000Source | 417,260,000Source | 269,367,000Source | 306,133,000Source | 428,678,000Source | 242,360,000Source | 212,554,000Source |
| Liabilities and EquityUSD | 412,898,000Source | 554,590,000Source | 298,877,000Source | 448,783,000Source | 581,963,000Source | 335,518,000Source | 486,479,000Source | 510,844,000Source | 377,378,000Source | 526,321,000Source | 469,192,000Source | 252,056,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 24,019,000Source | 70,603,000Source | 21,371,000Source | 19,803,000Source | 85,809,000Source | 19,195,000Source | 18,431,000Source | 173,938,000Source | 24,451,000Source | 39,482,000Source | 158,796,000Source | 21,972,000Source |
| Operating Lease, Liability, CurrentUSD | 4,350,000Source | 7,738,000Source | 4,449,000Source | 5,462,000Source | 8,567,000Source | 4,281,000Source | 6,510,000Source | 8,301,000Source | 4,138,000Source | 7,559,000Source | 7,909,000Source | 8,406,000Source |
| Accounts Payable, CurrentUSD | 3,166,000Source | 1,292,000Source | 3,746,000Source | 1,857,000Source | 1,635,000Source | 2,930,000Source | 2,188,000Source | 2,527,000Source | 2,289,000Source | 4,259,000Source | 3,277,000Source | 5,990,000Source |
| Operating Lease, Liability, NoncurrentUSD | 48,050,000Source | 53,576,000Source | 44,095,000Source | 49,281,000Source | 55,876,000Source | 45,469,000Source | 50,487,000Source | 58,131,000Source | 46,794,000Source | 51,648,000Source | 60,321,000Source | 17,530,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 15,532,000Source | 13,403,000Source | 13,003,000Source | 11,795,000Source | 10,999,000Source | 11,730,000Source | 7,579,000Source | 8,792,000Source | 17,682,000Source | 13,343,000Source | 11,325,000Source | 7,576,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 326,800,000Source | 449,300,000Source | 223,000,000Source | 354,000,000Source | 469,700,000Source | 254,900,000Source | 382,500,000Source | 327,400,000Source | 295,700,000Source | 420,000,000Source | 352,000,000Source | 188,700,000Source |
| Deferred Revenue, CurrentUSD | 351,000Source | 45,919,000Source | 173,000Source | 689,000Source | 60,497,000Source | 254,000Source | 1,352,000Source | 148,463,000Source | 342,000Source | 13,654,000Source | 132,261,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -39,717,000Source | -17,349,000Source | -143,750,000Source | 65,626,000Source | -6,685,000Source | -94,616,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,744,000Source | 5,087,000Source | 19,609,000Source | 17,915,000Source | 13,111,000Source | 9,895,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -41,695,000Source | -38,507,000Source | -128,512,000Source | -41,557,000Source | 139,803,000Source | -93,786,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 26,987,000Source | 4,783,000Source | 116,808,000Source | -27,798,000Source | -138,395,000Source | -148,650,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 44,000Source | 1,144,000Source | 1,041,000Source | 3,158,000Source | 5,614,000Source | 2,887,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 100,000Source | 350,000Source | 887,000Source | 102,964,000Source | 21,037,000Source | 479,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -14,608,000Source | -33,374,000Source | -10,817,000Source | 33,609,000Source | 22,445,000Source | -241,957,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 97,236,000Source | 81,999,000Source | 102,572,000Source | 76,432,000Source | 79,736,000Source | 71,787,000Source | 94,344,000Source | 105,161,000Source | 71,552,000Source | 49,107,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 1,699,000Source | 4,622,000Source | 14,717,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 5,116,000Source | 4,860,000Source | 5,150,000Source | 5,048,000Source | 4,744,000Source | 5,087,000Source | 19,609,000Source | 17,915,000Source | 13,111,000Source | 9,895,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 326,800,000Source | 449,300,000Source | 223,000,000Source | 354,000,000Source | 254,900,000Source | 382,500,000Source | 295,700,000Source | 420,000,000Source | 352,000,000Source | 188,700,000Source |
| DepreciationUSD | — | — | 1,200,000Source | 900,000Source | 800,000Source | 1,100,000Source | 805,000Source | 946,000Source | 4,096,000Source | 3,773,000Source | 2,841,000Source | 1,895,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 10,304,000Source | 9,971,000Source | 10,492,000Source | 10,922,000Source | 10,124,000Source | 10,274,000Source | 41,050,000Source | 38,465,000Source | 32,291,000Source | 30,639,000Source |
| Income Tax Expense (Benefit)USD | — | — | 654,000Source | -1,860,000Source | 35,000Source | 178,000Source | 38,000Source | 0Source | 924,000Source | 859,000Source | 18,741,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -44,134,000Source | -14,032,000Source | -42,763,000Source | -43,103,000Source | -39,717,000Source | -17,349,000Source | -143,750,000Source | 65,626,000Source | -6,685,000Source | -94,616,000Source |
| Operating ExpensesUSD | — | — | 48,665,000Source | 41,228,000Source | 45,861,000Source | 48,799,000Source | 43,178,000Source | 42,348,000Source | 183,319,000Source | 163,771,000Source | 132,175,000Source | 97,248,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 3,571,000Source | 5,766,000Source | 2,235,000Source | 3,924,000Source | 2,624,000Source | 4,441,000Source | 15,072,000Source | 19,474,000Source | 15,218,000Source | 2,632,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 100,000Source | 350,000Source | 425,000Source | — | 443,000Source | 195,000Source |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,614,000Source | 19,570,000Source | 898,000Source | 1,950,000Source | 875,000Source | 20,558,000Source | 25,421,000Source | 210,782,000Source | 129,013,000Source | — |
| Operating Income (Loss)USD | — | — | -47,051,000Source | -21,658,000Source | -44,963,000Source | -46,849,000Source | -42,303,000Source | -21,790,000Source | -157,898,000Source | 47,011,000Source | -3,162,000Source | -97,248,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 3,571,000Source | 5,766,000Source | 2,235,000Source | 3,924,000Source | 2,624,000Source | 4,441,000Source | 15,072,000Source | 19,474,000Source | 15,218,000Source | 2,632,000Source |
| Income Tax Expense (Benefit)USD | — | — | 654,000Source | -1,860,000Source | 35,000Source | 178,000Source | 38,000Source | 0Source | 924,000Source | 859,000Source | 18,741,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -44,134,000Source | -14,032,000Source | -42,763,000Source | -43,103,000Source | -39,717,000Source | -17,349,000Source | -143,750,000Source | 65,626,000Source | -6,685,000Source | -94,616,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.06Source | -0.35Source | -1.01Source | -1.04Source | -0.95Source | -0.42Source | -3.47Source | 1.76Source | -0.2Source | -3.02Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.06Source | -0.35Source | -1.01Source | -1.04Source | -0.95Source | -0.42Source | -3.47Source | 1.68Source | -0.2Source | -3.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 41,462,567Source | 40,629,602Source | 42,221,665Source | 41,338,752Source | 41,836,275Source | 41,073,732Source | 41,371,486Source | 37,306,363Source | 33,050,319Source | 31,293,312Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 41,462,567Source | 40,629,602Source | 42,221,665Source | 41,338,752Source | 41,836,275Source | 41,073,732Source | 41,371,486Source | 39,003,169Source | 33,050,319Source | 31,293,312Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 924,000Source | 859,000Source | 18,741,000Source | — |
| General and Administrative ExpenseUSD | — | — | 10,304,000Source | 9,971,000Source | 10,492,000Source | 10,922,000Source | 10,124,000Source | 10,274,000Source | 41,050,000Source | 38,465,000Source | 32,291,000Source | 30,639,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | -43,480,000Source | -15,892,000Source | -42,728,000Source | -42,925,000Source | -39,679,000Source | -17,349,000Source | -142,826,000Source | 66,485,000Source | 12,056,000Source | — |
| Operating ExpensesUSD | — | — | 48,665,000Source | 41,228,000Source | 45,861,000Source | 48,799,000Source | 43,178,000Source | 42,348,000Source | 183,319,000Source | 163,771,000Source | 132,175,000Source | 97,248,000Source |
| Research and Development ExpenseUSD | — | — | 38,361,000Source | 31,257,000Source | 35,369,000Source | 37,877,000Source | 33,054,000Source | 32,074,000Source | 142,269,000Source | 125,306,000Source | 99,884,000Source | 66,609,000Source |
Filing attachments
tm2614944d1_ex99-1.htm · 8-K · 2026-05-19
EX-99.1 2 tm2614944d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Meet Andrew and JJ, living with Duchenne muscular dystrophy Corporate Presentation May 2026 ─────────────────────────────────────────────────────────────── Disclaimer May 2026 2 This presentation has been prepared by Entrada Therapeutics, Inc. (“Entrada”) and shall not constitute an offer to sell or a solicitation of an offer to buy securities or an invitation or inducement to engage in investment activity nor shall …
Read attachment ↗tm253290d1_ex99-1.htm · 8-K · 2025-01-15
EX-99.1 2 tm253290d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 2025 J.P. Morgan Healthcare Conference NASDAQ: TRDA Disclaimer This presentation has been prepared by Entrada Therapeutics, Inc. (the “Company”) and shall not constitute an offer to sell o r a solicitation of an offer to buy securities or an invitation or inducement to engage in investment activity nor shall there be any sale of securities in any jurisdiction in which such of fer, solicitation or sale would be unlawful prior to regi…
Read attachment ↗